open access

Vol 15, No 4 (2010)
Published online: 2010-07-01
Submitted: 2010-02-24
Get Citation

Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment

Krzysztof Małecki, Bogdan Gliński, Anna Mucha-Małecka, Janusz Ryś, Anna Kruczak, Krzysztof Roszkowski, Marta Urbańska-Gąsiorowska, Marcin Hetnał
DOI: 10.1016/j.rpor.2010.06.001
·
Rep Pract Oncol Radiother 2010;15(4):87-92.

open access

Vol 15, No 4 (2010)
Published online: 2010-07-01
Submitted: 2010-02-24

Abstract

Background

The optimal management of advanced laryngeal and hypopharyngeal cancers (L&HC) must involve consideration of both survival and functional effect of the given treatment approach. Despite over two decades of investigations of several treatment options, including surgery, radiotherapy, chemotherapy or some combinations thereof, little consensus exists as to which treatment offers the best survival, together with functional speech and swallowing.

Aim

To determine predictive and prognostic value of p53, EGFr, Ki-67 in patients with advanced laryngeal and hypopharyngeal cancer, treated with larynx preservation intent.

Materials and methods

Thirty-three patients received 2–3 cycles of induction chemotherapy (ICHT) consisting of cisplatin and fluoruracil and underwent subsequent radical radiotherapy. Immunohistochemical analyzes of p53, EGFr and Ki-67 were performed.

Results

Response to ICHT was obtained in 24 patients (75%). Better response to ICHT was correlated only with EGFr expression (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.04, RR[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1.91). The 5-year loco-regional control (LRC) and disease-specific survival (DSS) rates were 48% and 57%, respectively. The 5-year larynx preservation rate was 68% in responders to ICHT compared to 21% in non-responders (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.02). It was also higher in patients without EGFr expression (but not significantly, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.43).

Conclusion

Lack of EGFr expression is a favorable predictive factor for response to ICHT. Neither p53 nor Ki-67 have predictive and prognostic value in larynx preservation treatment.

Abstract

Background

The optimal management of advanced laryngeal and hypopharyngeal cancers (L&HC) must involve consideration of both survival and functional effect of the given treatment approach. Despite over two decades of investigations of several treatment options, including surgery, radiotherapy, chemotherapy or some combinations thereof, little consensus exists as to which treatment offers the best survival, together with functional speech and swallowing.

Aim

To determine predictive and prognostic value of p53, EGFr, Ki-67 in patients with advanced laryngeal and hypopharyngeal cancer, treated with larynx preservation intent.

Materials and methods

Thirty-three patients received 2–3 cycles of induction chemotherapy (ICHT) consisting of cisplatin and fluoruracil and underwent subsequent radical radiotherapy. Immunohistochemical analyzes of p53, EGFr and Ki-67 were performed.

Results

Response to ICHT was obtained in 24 patients (75%). Better response to ICHT was correlated only with EGFr expression (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.04, RR[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]1.91). The 5-year loco-regional control (LRC) and disease-specific survival (DSS) rates were 48% and 57%, respectively. The 5-year larynx preservation rate was 68% in responders to ICHT compared to 21% in non-responders (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.02). It was also higher in patients without EGFr expression (but not significantly, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.43).

Conclusion

Lack of EGFr expression is a favorable predictive factor for response to ICHT. Neither p53 nor Ki-67 have predictive and prognostic value in larynx preservation treatment.

Get Citation

Keywords

Larynx preservation; Induction chemotherapy; p53; EGFr; Ki-67

About this article
Title

Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 15, No 4 (2010)

Pages

87-92

Published online

2010-07-01

DOI

10.1016/j.rpor.2010.06.001

Bibliographic record

Rep Pract Oncol Radiother 2010;15(4):87-92.

Keywords

Larynx preservation
Induction chemotherapy
p53
EGFr
Ki-67

Authors

Krzysztof Małecki
Bogdan Gliński
Anna Mucha-Małecka
Janusz Ryś
Anna Kruczak
Krzysztof Roszkowski
Marta Urbańska-Gąsiorowska
Marcin Hetnał

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl